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The development of vaccines against human papillomaviruses (HPVs) has long been hampered by the inability to grow
HPVs in tissue culture and the lack of an efficient neutralization assay. To date, less than 10% of more than 100 different HPV
types can be grown in athymic and “SCID” mouse xenograft systems or raft culture systems. Recently, the in vitro generation
of HPV pseudovirions and their use in neutralization assays were demonstrated. The major shortcomings of the current
approaches to HPV neutralization are the lack of HPV virions for most types for the xenograft methods and the time-
consuming and inefficient generation of infective pseudovirions for the latter methods, which precludes their use in
large-scale HPV clinical trials or epidemiological studies. We describe here a novel and efficient approach to generating
pseudovirions in which HPV virus-like particles (VLPs) are coupled to the b-lactamase gene as a reporter. We show that it
is not necessary to encapsidate the reporter gene constructs into the pseudovirions. Using sera from human volunteers
immunized with HPV-11 VLPs expressed in yeast, we demonstrate that our novel neutralization assay compares favorably
with the athymic mouse neutralization assay. Furthermore, our assay was used to define neutralizing monoclonal antibodies
to HPV-6, which were previously unknown. © 2000 Academic PressINTRODUCTION
Infection of cutaneous, genital, and respiratory epithelia
with human papillomaviruses (HPVs) causes benign as
well as malignant proliferative lesions. From the more than
100 HPV types described today, HPV-16 and -18 cause
more than 70% of all cervical cancers (Bosch et al., 1995),
and HPV-6 and -11 cause ;90% of condyloma, benign
lesions of the genital and respiratory tract (Gissmann et al.,
1983). Although the prevalence of HPV disease is on the
rise, the prevention and treatment of HPV disease are
ineffective and limited predominantly to developed coun-
tries. In developing countries, where screening for cervical
cancer precursors is either absent or not accessible to
most women, cervical cancer is the most common malig-
nancy in women (Koutsky et al., 1988). Today, it is generally
accepted that an effective prophylactic vaccine has the
highest chance of preventing many cases of HPV-related
disease. Several groups have already begun early phase
clinical trials. Until the efficacy of current vaccine candi-
dates based on the induction of HPV neutralizing antibod-
ies is proved in humans and surrogates of protection have
been established, a broadly applicable HPV neutralization
assay is highly desirable to test and compare various vac-
1 To whom correspondence and reprint requests should be addressed
at WP16-101, Merck Research Laboratories, Sumneytown Pike, West Point,
PA 19486. Fax: 215-652-2142. E-mail: Kathrin_Jansen@Merck.com.
0042-6822/00 $35.00
Copyright © 2000 by Academic Press
All rights of reproduction in any form reserved.
570cine formulations. Unfortunately, only a small number of
HPV types have been successfully grown in mouse xeno-
graft or raft culture systems (Bonnez et al., 1998; Chris-
tensen et al., 1997; Kreider et al., 1987; Meyers et al., 1997).
For many years, the neutralizing potential of immune sera
could be tested only in mouse xenograft systems. Several
ways to produce pseudovirions have also been described
(Kawana et al., 1998; Roden et al., 1996; Rossi et al., 2000;
Touze and Coursaget, 1998; Unckell et al., 1997; Zhao et al.,
1998); however, current methods to produce these
pseudovirions are inefficient (Kawana et al., 1998; Touze
and Coursaget, 1998; Unckell et al., 1997) or time consum-
ing (Roden et al., 1996; Zhao et al., 1998) and thus limit their
use in testing large numbers of sera from clinical trials or
epidemiology studies. We report here the development of a
novel and efficient HPV neutralization assay that is broadly
applicable to a number of HPV types. Furthermore, we
show for the first time comparative data using our assay
and the athymic mouse xenograft assay that demonstrate
the usefulness of this assay to reliably test immune sera
from clinical trials. Finally, we describe a panel of monoclo-
nal antibodies that neutralize HPV-6 pseudovirions.
RESULTS
Efficient infection of C33A cells with HPV-11 and -16
pseudovirions
The efficiency of HPV L1 or L1 1 L2 pseudovirions to
infect C33A cells was compared in the initial phase of
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571NEUTRALIZATION OF HPV PSEUDOVIRIONSthe development of the assays. The protocol of infection/
neutralization described here was followed; the plates
were examined under a fluorescent microscope, and the
number of blue cells was counted in each well. For all
HPV types tested, L1 pseudovirion infection of C33A
cells was less efficient than infection with L1 1 L2
seudovirions (Table 1). HPV L1 1 L2 pseudovirions
ere so efficient in infecting cells (.400 blue cells/well)
hat it was impractical to count all blue cells per well.
low cytometry was used to determine the infection
fficiency to be 15–40% depending on the pseudovirion
ype and/or experiment (data not shown). Based on these
esults, L1 1 L2 pseudovirions were chosen for all sub-
equent experiments with the exception of HPV-18, for
hich L1 1 L2 VLPs were not available.
omparison of the HPV-11 athymic mouse and HPV-
1 pseudovirion neutralization assays
To compare our pseudoneutralization assay with the
ore established athymic mouse neutralization assay
Bryan et al., 1997), we compared assay results gener-
ted in both assays using a panel of immune sera from
uman volunteers immunized with HPV-11 VLPs ex-
ressed in yeast. Sera were diluted at 1:50 for the athy-
ic mouse neutralization assay because the assay had
een validated with this serum dilution. For the pseudo-
eutralization assay, sera had to be diluted at 1:100
ecause lower serum dilutions resulted in unacceptable
erum effects (i.e., partial, nonspecific inhibition of
seudovirion uptake by nonimmune sera). As shown in
able 2, none of the preimmune sera were neutralizing in
ither of the assays. Sera with low titers [,10–57 mMU/
l] also were not neutralizing in the assays. Sera with
iters of $860 mMU/ml were neutralizing in both assays.
n the titer range of 250–860 mMU/ml, the pseudoneu-
ralization assay showed more consistent neutralization
ompared with the athymic mouse neutralization assay.
verall, the HPV-11 RIA titers correlated well with neu-
TABLE 1
Comparison of C33A Cell Infection Using HPV L1 or
L1 1 L2 Pseudovirions
Pseudovirion
Pseudovirion
composition
No. of
experiments
No. of infected
cells
HPV-16 L1 27 87 6 8 (S.E.M.)
HPV-16 L1 1 L2 2 .400
HPV-11 L1 8 155 6 21 (S.E.M.)
HPV-11 L1 1 L2 6 .400
Note. Duplicate wells of C33A cells infected with pseudovirions were
monitored for BLAM expression using a fluorescent microscope. Blue
cells (BLAM-expressing cells) were counted in each well, and the
average number of blue cells and S.E.M. are shown. .400 indicates
that the number of blue cells were too numerous to count and that
counting was stopped at 400 cells.ralization measured in both assays, indicating that thePV-11 RIA assay by itself detects predominantly func-
ional (i.e., neutralizing antibodies).
ype-specific neutralization using HPV pseudovirions
To test whether our pseudoneutralization assay mea-
ures type-specific, neutralizing responses, HPV-6 and
18 pseudovirions were also prepared, and neutralization
ssays similar to the HPV-11 and -16 assays were es-
ablished. For type 18 only, HPV-18 L1 instead of L1 1 L2
seudovirions were used for the experiments, because
PV-18 L1 1 L2 VLPs were not available at the time and
he HPV-18 L1 pseudovirions infected cells more effi-
iently than L1 pseudovirions from other HPV types (data
ot shown). Antisera raised in African green monkeys
gainst HPV-11, -6, -16, and -18 L1 VLPs as described
reviously (Lowe et al., 1997) were used for this experi-
ent. All antisera tested had titers of at least 30,000
MU/ml in their respective serological assays. Note that
TABLE 2
Comparison of Athymic Mouse and Pseudoneutralization Assays
Using a Panel of Preimmune and Postimmune Sera from Human
Volunteers Immunized with HPV-11 VLPs Expressed in Yeast
Serum
no.
HPV-11 RIA titer
(mMU/ml)a
Neutralization
Athymic mouseb Pseudoneutralizationc
Pre Post Pre Post Pre Post
1 ,10 ,10 2 2 2
2 ,10 18 2 2 2 2
3 ,10 29 2 2 2 2
4 ,10 30 2 2 2 2
5 ,10 46 2 2 2 2
6 ,10 57 2 2 2 2
7 ,10 137 2 2 2 1
8 ,10 154 2 2 2 2
9 ,10 250 2 2 2 1
10 ,10 270 2 1 2 1
11 ,10 290 2 1 2 1
12 ,10 300 2 1 2 1
13 ,10 310 2 1 2 1
14 ,10 390 2 2 2 1
15 ,10 440 2 2 2 1
16 ,10 730 2 2 2 1
17 ,10 760 2 2 2 1
18 ,10 860 2 1 2 1
19 ,10 970 2 1 2 1
20 ,10 1000 2 1 2 1
21 ,10 1260 2 1 2 1
22 ,10 1310 2 1 2 1
23 ,10 1310 2 1 2 1
24 ,10 1560 2 1 2 1
25 ,10 2900 2 1 2 1
26 ,10 3050 2 1 2 1
27 ,10 5320 NT NT 2 1
Note. NT, not tested.
a Titer not corrected for dilution factor used in neutralization assay.
b Sera assayed at 1:50.
c Sera assayed at 1:100.
assay
572 YEAGER ET AL.the immune sera tested in the various neutralization
assays to determine cross-reactivity were not pre-
screened to achieve 100% neutralization at the 1:100
dilution. As shown in Figs. 1A and 1B, neutralization of
HPV-16 and -18 pseudovirions was type specific even at
the 1:100 dilution. The HPV-6 and -11 pseudovirion as-
says exhibited cross-reactivity with respect to HPV-6 and
-11 sera at the 1:100 serum dilution but were discrimi-
nating between these two highly related types at the
higher dilutions tested (Figs. 1C and 1D). The HPV-6
neutralization assay was type specific for HPV-16 and -18
sera (Fig. 1D); however, the HPV-11 neutralization assay,
although specific for HPV-18 sera, was slightly cross-
reactive at the 1:100 dilution of the HPV-16 serum (Fig.
FIG. 1. Neutralization of HPV pseudovirions by sera from African green
C33A cells (triplicate wells) were infected with either HPV-16 (panel A)
presence of preimmune and immune sera from one African green mo
VLPs expressed in yeast. The cutoff for positive neutralization in each1C).Identification of HPV-6 neutralizing monoclonal
antibodies
For the consistent manufacture of VLP-based vac-
cines, the characterization of VLP lots using monoclonal
antibodies (MAbs) is critical. MAbs that neutralize HPV-6
have not been described due to the lack of an HPV-6
neutralization assay. We used our HPV-6 pseudovirion
assay to test a panel of MAbs generated against intact
HPV-6 VLPs. These MAbs were shown to be specific for
the binding of HPV-6 VLPs (Christensen et al., 1994b,
1996a,b). As shown in Table 3, the HPV-6 type-specific
MAbs were potent in neutralizing the HPV-6 pseudoviri-
ons but not the HPV-11 or -16 pseudovirions. One of the
ys immunized with HPV-6, -11, -16, and -18 L1 VLPs expressed in yeast.
8 (panel B), HPV-11 (panel C), or HPV-6 (panel D) pseudovirions in the
munized with either HPV-16, HPV-18, HPV-11, or HPV-6 (as indicated)
was defined as $40% neutralization.monke
, HPV-1
nkey imHPV-6 MAbs, H6.J54, neutralized both HPV-6 and -11
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573NEUTRALIZATION OF HPV PSEUDOVIRIONSpseudovirions. The same MAb, which is cross-reactive
with HPV-11 VLPs, was previously shown to neutralize
HPV-11 in the athymic mouse neutralization assay (Chris-
tensen et al., 1996b).
DISCUSSION
Kreider et al. (1987) first demonstrated the successful
roduction of an infectious HPV, HPV-11, in the athymic
ouse xenograft system more than 15 years ago. Since
hat time, fewer than 10 HPV types have been success-
ully propagated using methods like the athymic and
CID mouse xenograft system or a raft culture system
Bonnez et al., 1998; Christensen et al., 1997; Meyers et
l., 1997). Recognizing the difficulties of growing HPVs in
issue culture, several groups have embarked on devel-
ping methods to create infectious HPV pseudovirions in
itro for use in neutralization assays or to study events
fter HPV infection. After the discovery that HPV VLPs
esembling native virions can be produced in a variety of
xpression systems (Christensen et al., 1994a; Ha-
ensee et al., 1993; Hofmann et al., 1995; Kirnbauer et al.,
992; Li et al., 1997; Nardelli-Haefliger et al., 1997; Rose
t al., 1993; Sasagawa et al., 1995; Zhou et al., 1991),
ome groups reported the encapsidation of reporter
lasmids into the VLPs (Roden et al., 1996; Rossi et al.,
000; Touze and Coursaget, 1998; Unckell et al., 1997;
hao et al., 1998) and the successful infection of cells
nd tissues using these pseudovirions. Although most of
hese reported methods generate pseudovirions that are
easonable research tools, the methods are inefficient
nd time consuming. Furthermore, the pseudovirions are
ifficult to purify and characterize for use in neutraliza-
ion assays necessary to monitor large-scale clinical and
pidemiological studies. Most groups have chosen to
ncapsidate a reporter plasmid into the VLPs, but we
ound that encapsidation of the reporter is unnecessary.
hemically cross-linking the PCR-generated reporter, in
his case, the b-lactamase (BLAM) gene driven by the
human cytomegalovirus (CMV) promoter, to the outside
TABLE 3
Identification of HPV-6 MAbs that Neutralize HPV-6 Pseudovirions
MAba
Neutralization assay
HPV-6 HPV-11 HPV-16
H6.N8 1 2 2
H6.M48 1 2 2
H6.B10.5 1 2 2
H6.J54 1 1 2
H11.B2 ND 1 ND
H16.V5 ND ND 1
Note. ND, not done.
a All MAbs (Christensen et al., 1996a, 1990, and 1996b) were tested
t a 1:10,000 dilution.of the VLPs is sufficient. A major advantage of thisapproach is that highly purified and well-characterized
HPV VLPs can be used. We report here that up to 40% of
target cells can be consistently infected with these
pseudovirions. One other group had attempted a similar
approach but had little success, demonstrating less than
1% infection of target cells (Muller et al., 1995). Further-
more, the investigators needed coinfection with a repli-
cation-deficient adenovirus to increase infection effi-
ciency. This approach would not be feasible for testing
human sera because many individuals carry adenovirus-
neutralizing antibodies, which would obscure the HPV-
specific neutralization. We suspect that the coupling of
their much larger reporter construct, an 8.6-kb plasmid,
to the VLPs may have inhibited the uptake of the
pseudovirions. In addition, a different coupling ratio of
reporter construct to VLP was chosen. We actually found
in our assay that increasing the ratio of reporter con-
struct to VLP by only two-fold nearly abolished infection
efficiency (data not shown). As Unkell et al. (1997) have
shown previously for pseudovirions with encapsidated
reporters, we also demonstrated that L2 inclusion into
the VLP dramatically improved infection efficiency for
HPV-16 and -11 pseudovirions (Table 1).
We next asked whether our pseudoneutralization as-
says exhibit type specificity. Because immunization with
nondenatured VLPs generates predominantly type-spe-
cific and neutralizing antibody responses (Christensen et
al., 1994a; Roden et al., 1996; White et al., 1998) and as
hown in animal models’ protective antibodies (Breitburd
t al., 1995; Jansen et al., 1995; Kirnbauer et al., 1996), a
functional test like a neutralization assay should be spe-
cific for these types of antibodies. Four high-titered im-
mune sera generated in African green monkeys immu-
nized with HPV-6, -11, -16, or -18 L1 VLPs expressed in
yeast together with their preimmune serum controls
were tested in all four HPV neutralization assays. All
neutralization assays were predominantly type specific
at all of the serum dilutions tested (Fig. 1), with signifi-
cant cross-reactivity observed only between the closely
related types HPV-6 and -11 at the lowest serum dilution
(1:100) tested. This cross-reactivity was alleviated at the
higher serum dilutions. The limited cross-neutralization
between HPV-6 and -11 immune sera is not unexpected
because the L1 amino acid sequences of HPV-6 and -11
share a 92% homology, and numerous MAbs cross-reac-
tive between HPV-6 and -11 have been generated (Chris-
tensen et al., 1996b). In addition, HPV-6 VLP-specific
MAbs have been described that neutralize HPV-11 viri-
ons in the athymic mouse xenograft assay (Christensen
et al., 1996b). In this report, we also show that an addi-
tional HPV-6 MAb, H6.J54, is neutralizing in both the
HPV-11 and -6 pseudoneutralization assay (Table 3), fur-
ther supporting the notion that limited cross-neutraliza-
tion between HPV-11 and -6 sera indeed exists. It will be
interesting to see whether cross-protection can also be
achieved after immunization with HPV-6 or -11 VLPs in
the context of clinical trials. We also present evidence for
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574 YEAGER ET AL.the first time that three HPV-6 type and VLP-specific
MAbs, H6.B10.5, H6.N8, and H6.M48 (Christensen et al.,
996a,b), are neutralizing (Table 3). These three antibod-
es bind to neither denatured HPV-6 VLPs nor native
PV-11 VLPs, and they do not neutralize HPV-11 (Table
). Because the characterization of VLP-based vaccines
s partially based on binding of MAbs recognizing those
pitopes, which elicit neutralizing responses, this assay
ay assist in the identification of these important anti-
ody tools. The fact that the pseudoneutralization assay
s viable for four of four HPV types tested suggests that
t likely is functional for most, it not all, HPV types for
hich VLPs can be generated. In addition, the mapping
f these epitopes should also be facilitated, because
utant VLPs can be easily expressed and used in these
ssays. Furthermore, the assay may guide the develop-
ent of chimeric VLPs harboring neutralizing epitopes
or several HPV types, which could ultimately reduce the
otal number of VLP types in a vaccine to increase
overage for a larger number of clinically relevant types.
The most important concern with all pseudovirion neu-
ralization assays is that infectious native virions are not
sed. The use of native virions in neutralization assays
ay change the results obtained with pseudovirions. In
ddition, because our assay does not encapsidate the
eporter gene, neutralizing antibodies that affect pro-
esses after initial binding and entry into the cell, such
s decapsidation, may be missed. We addressed these
ssues by comparing the HPV-11 athymic mouse neutral-
zation assay with our HPV-11 pseudoneutralization as-
ay using a panel of immune sera from human volun-
eers immunized with HPV-11 VLPs. The panel of sera
overed a range of titers differing by more than 300-fold.
o significant differences were seen when comparing
he results obtained in both assays, indicating that our
seudoneutralization assay can detect the majority of
unctional antibodies elicited after immunization with
LPs. These results also suggest that the mechanism of
ell infection seems to be the same for infectious virions
nd pseudovirions. In addition, the HPV-11 pseudoneu-
ralization assay detected similar amounts of functional
ntibodies in sera generated in African green monkeys
mmunized with native virions or VLPs expressed in
east (data not shown). We also demonstrated in this
eport that our HPV-11 RIA, which measures HPV-11
LP-specific antibodies, appears to be a good surrogate
ssay to detect neutralizing antibodies. All human sera
ith titers of at least 250 mMU/ml were consistently
eutralizing in our HPV-11 pseudoneutralization assay.
onsidering that the actual titer of the human sera in the
ssay was 100-fold lower than the undiluted titer and
as sufficient to neutralize the large number of
seudovirions used in the assay (6 3 109 particles),
emonstrating that potent neutralizing antibodies can be
licited in humans after immunization with HPV VLPs.
he protective efficacy against natural infection with HPVnd HPV-related diseases now needs to be proved in
uman clinical trials.
MATERIALS AND METHODS
eneration of BLAM reporter gene
A 1.8-kb fragment of the pCDNA3-BLAM vector (Aurora
ioscience Corp., San Diego, CA) encoding the 591-bp
uman CMV promoter, the 809-bp BLAM gene, and the
35-bp bovine growth hormone poly-A tail sequences
as PCR synthesized using sense and antisense modi-
ied nucleotides. The 59 modified oligonucleotides (Sigma-
enosys, The Woodlands, TX) were designed with a
iotin group at the 59 end of the sense strand and an
mino group at the 59 end of the antisense strand. After
CR amplification, the PCR product (BLAMF59-bio) was
purified using a tip-500 Qiagen (Valencia, CA) Plasmid
Purification method according to the manufacturer’s in-
struction and quantified by UV spectrometry at 260 nm.
Generation of HPV pseudovirions
HPV VLPs were expressed in yeast and purified as
described previously (Cook et al., 1999; Hofmann et al.,
1995 and 1996; Neeper et al., 1996). Purified HPV VLPs
were coupled to the BLAM reporter gene at a VLP/BLAM
molar ratio of 1:1 using sulfo-SMCC (SSMCC), a bifunc-
tional coupling reagent (Pierce, Rockford, IL) according
to the manufacturer’s instruction. Briefly, the BLAMF59-
bio reporter construct (see earlier) was first coupled to
SSMCC for 1 h at 37°C. Excess coupling reagent was
then removed by passage through Sephadex G-50, fine
Quick Spin columns (Roche Molecular Biochemicals, In-
dianapolis, IN), and the material (BLAM-SSMCC) was
sterile filtered through a 0.22-mm Millex-GV4 filter unit
Millipore, Bedford, MA). Then 1.12 mg of BLAM-SMCCC
as incubated with 20 mg of VLPs at 4°C for 3 days to
enerate the pseudovirions. Pseudovirions were either
sed directly in the neutralization assays or stored frozen
n aliquots at 270°C for future use.
PV pseudoneutralization assay
The human cervical carcinoma cell line C33A was
btained from American Type Culture Collection (HTB-
1) and cultured in complete Dulbecco’s modified Eagle’s
edium (DMEM plus 10% fetal calf serum; GIBCO, Grand
sland, NY). Cells (1 3 104/well) were seeded into 96-well
plates and cultured for 2 days at 37°C before infection.
Test sera were diluted at least 1:50 in OPTI-MEM me-
dium (GIBCO), and pseudovirions were diluted to 2.4 3
1011 particles/ml in the same medium. The culture me-
ium was removed from the C33A cells, and 25 ml of
iluted serum sample was added to each well before the
ddition of 25 ml of diluted pseudovirions (6 3 109 par-
ticles/well). The final dilution of sera in the assay was
1:100. Cells were grown overnight at 37°C and then fed
with 100 ml of complete DMEM. After an additional 24 h
s
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575NEUTRALIZATION OF HPV PSEUDOVIRIONSof growth at 37°C, the medium was removed from the
cells and cells were washed with 100 ml of OPTI-MEM.
To detect BLAM activity in the cells, 50 ml of the BLAM
ubstrate CCF4/AM (5 mM; Aurora Biosciences Corpo-
ation, San Diego, CA) (Zlokarnik et al., 1998) in OPTI-
MEM containing 1 mg/ml Pluronic F-127, 3.3% PEG, 1.15%
Enhanced Substrate Solution (Aurora Biosciences Cor-
poration), 2.5 mM probenecid (Sigma, St. Louis, MO), and
16.7 mM Trolox (Aldrich Chemical Co., Milwaukee, WI)
was added. Cells were incubated at 37°C for 2 h, and
plates were evaluated under a fluorescent microscope
(excitation filter, 405 nm; emission filter, 435 nm; long-
pass) to determine the number of blue (BLAM-positive)
cells. Duplicate wells were analyzed for each test con-
dition. Alternatively, fluorescence readings at 460 nm
were obtained using a Cytofluor (PerSeptive Biosystems,
Framingham, MA) multiwell plate reader. For this read-
out, triplicate wells were analyzed for each test condi-
tion. If HPV neutralizing antibodies are present in test
sera, pseudovirion entry into the cell and BLAM expres-
sion are inhibited, thus lowering the level of developed
blue fluorescence. The percentage of neutralization for a
given sample is calculated as follows:
S1 2 ~Immune sera 2 no pseudovirions!~Preimmune sera 2no pseudovirions!D *100
here “no pseudovirions” signifies the background fluo-
escence in wells that did not contain pseudovirions. The
utoff for the detection of neutralization was derived from
epeated testing of negative and positive sera (50 sera
otal) as well as serum dilutions to determine the vari-
bility of the assay, which gave a standard deviation of
2% neutralization. The negative cutoff was then set at
hree standard deviations above 0% neutralization
536%) and rounded to ,40%.
low cytometry
Because infection with L1 1 L2 pseudovirions yielded
oo many blue cells to count by fluorescence microscopy,
low cytometry was used to better estimate infection
fficiency. The assay was scaled up to 12-well plates,
nd CCF2/AM substrate was used. After infection, C33A
ells cultured for 2 days in 12-well plates were loaded
ith CCF2/AM substrate for BLAM and incubated for 1 h
t room temperature. Then cells were washed with cold
BS (Ca12, Mg12 free; GIBCO), followed by incubation for
min at room temperature with cold 0.05% trypsin
GIBCO). Trypsin was inactivated with 10% FBS (GIBCO)
n PBS; then cells from each well were harvested into
-ml polystyrene tubes (FALCON; Becton Dickinson,
ranklin Lakes, NJ), followed by centrifugation at 1500
pm for 5 min at room temperature. Cells were sus-
ended in 0.5 ml of cold sort buffer (PBS minus Ca12,
g12, 25 mM HEPES, 0.1% BSA) and kept on ice until
nalysis.
Cells were analyzed with the Becton Dickinson FACSantage SE, with a Coherent 170 C4 laser at 488 nm
perated at 200 mW for scatter detection and a Coherent
02C laser at 406.9 nm operated at 50 mW for excitation
f the CCF2 dye. Fluorescence was collected through a
30/30 (“green”) and a 450/30 (“blue”) filter with color
ompensation and log amplification. Data were analyzed
sing Becton Dickinson CellQuest software. The number
f events analyzed was 10,000 per sample. Control cells
ot treated with pseudovirions were used to set the gate
hreshold for positive cells in the blue channel.
thymic mouse neutralization assay
The athymic mouse neutralization assay was per-
ormed as described previously (Bryan et al., 1997).
riefly, preimmune and postimmune sera were collected
s part of an ongoing immunogenicity trial from consent-
ng human volunteers immunized with yeast-expressed
LPs after institutional review board approval was ob-
ained. Sera were diluted 1:50 and incubated with ;109
HPV-11 virions and human foreskin fragments. The fore-
skin fragments were implanted under the renal capsule
of athymic mice. Three mice or six foreskin implants
were used for each test serum. Implants were analyzed
for evidence of HPV-11 infection by histology and DNA in
situ hybridization. Evidence of HPV-11 infection by either
method classified any given test serum as nonneutraliz-
ing. Conversely, any test serum that completely pre-
vented evidence of HPV-11 infection by either method
was considered neutralizing.
HPV-11 L1 VLP radioimmunoassay (RIA)
The HPV-11 RIA is a serological assay that is based on
the competition of immune sera for limiting amounts of
epitopes on HPV-11 L1 VLPs with an HPV-11 VLP-specific
conformation-dependent mouse MAb (MAb 8740; Chemi-
con, Temecula, CA). MAb 8740 is the same MAb as
H11.B2 (Christensen et al., 1990). Polystyrene beads (0.25
inch with specular finish; Precision Plastic Ball Co.,
Franklin Park, IL) were coated with yeast-derived HPV-11
VLPs at 150 ng/ml in PBS for 1 h at room temperature (5
beads/ml) with mild agitation. Beads were washed in
deionized water and then stored submerged in PBS at
4°C until further use. Equal volumes of immune sera (100
ml) and diluted MAb 8740 (1:160,000 in PBS plus 1% BSA
plus 0.05% Tween 20) were mixed in 1 well of a 20-well
Abbott assay plate. A single HPV-11-coated bead was
added to each well, and assay plates were sealed and
incubated overnight at room temperature. Beads were
washed with deionized water and incubated with 125I
goat anti-mouse IgG (NEN Life Sciences, Boston, MA) for
2.5 h. Beads were again washed in deionized water,
transferred to carrier tubes, and counted in a gamma-
counter. The relative inhibition of MAb 8740 binding was
compared with a standard curve using a four-parameter
logistic curve fit. The immune serum used for the stan-
dard curve was assigned an arbitrary value expressed in
BC
C
576 YEAGER ET AL.mMU/ml. The cutoff value for a serological response was
determined relative to the standard curve using multiple
runs of monkey preimmune and immune sera as well as
normal human sera from individuals negative for HPV by
PCR and having a low risk of HPV exposure. The cutoff
value for the HPV-11 RIA was defined as 10 mMU/ml.
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